International Clinical Practice Guidelines for Acute Deep Vein Thrombosis: A Comparative Review of Recommendations, Evidence Gaps, and Emerging Trends

1. Introduction

Deep vein thrombosis (DVT) remains a major global health challenge and an important contributor to morbidity, mortality, and healthcare expenditure. As a principal manifestation of venous thromboembolism (VTE), acute DVT is associated with life-threatening pulmonary embolism (PE), recurrent thrombotic events, post-thrombotic syndrome (PTS), and chronic venous insufficiency (CVI). Early diagnosis and timely initiation of evidence-based treatment are therefore essential to reduce complications and improve patient outcomes [1,2].

Over the past decade, advances in diagnostic imaging, anticoagulant therapy, catheter-based interventions, and risk stratification have substantially transformed the management of acute DVT. Concurrently, several international societies have published updated clinical practice guidelines designed to standardize care and support evidence-based decision-making [3,4,5,6,7,8]. Although these guidelines share common therapeutic goals, important differences remain regarding diagnostic algorithms, D-dimer utilization, imaging strategies, anticoagulant selection, treatment duration, outpatient management, and indications for invasive interventions [3,4,5,6,7,8].

These variations should not necessarily be interpreted as contradictions. Rather, they frequently reflect differences in healthcare systems, resource availability, regional epidemiology, reimbursement structures, and interpretation of available evidence [9,10,11]. Recent work on guideline contextualization emphasizes that high-quality recommendations often require adaptation to local realities rather than universal adoption [9,10]. Understanding these differences is therefore important for clinicians, researchers, and policymakers seeking to apply recommendations appropriately within their own healthcare environments.

This review compares contemporary international guidance for the diagnosis and management of acute DVT, with emphasis on areas of consensus, major differences, clinically relevant controversies, and priorities for future research.

2. Materials and Methods

This narrative review compares contemporary international recommendations for the diagnosis and management of acute (DVT). Guidelines were selected through consensus among the co-lead authors and senior author following a structured literature review. Repository guideline searches were performed through May 2026 to identify the most recent versions of evidence-based recommendations from major international societies.

Eligible documents included guidelines published by the American Society of Hematology (ASH), the European Society for Vascular Surgery (ESVS), the National Institute for Health and Care Excellence (NICE), the American College of Chest Physicians (CHEST), and the Japanese Circulation Society/Japanese Pulmonary Circulation and Pulmonary Hypertension Society (JCS/JPCPHS). We also included the International Society on Thrombosis and Haemostasis (ISTH), however, since the ISTH does not provide a unified guideline covering the complete diagnostic and therapeutic management of acute DVT, relevant ISTH Scientific and Standardization Committee (SSC) guidance documents addressing specific clinical scenarios were reviewed separately. The Asian Venous Thromboembolism guidelines were initially considered, but upon review, it was observed that guidelines recommendations focused only on thromboprophylaxis [7] and therefore, was eliminated from comparison list. Guideline publication year, type of grading methodology and strength of recommendation are summarized in Table 1.

Recommendations were categorized according to diagnostic evaluation, anticoagulant selection, treatment duration, compression therapy, outpatient management, catheter-directed interventions, special populations, and pediatric venous thromboembolism (Table 2). Areas of agreement, disagreement, and evidence uncertainty were identified through comparative analysis. Attention was given to recommendations supported by low-certainty evidence, regional differences in healthcare resources, and emerging therapeutic strategies likely to influence future guideline updates.

It is important to address that variation in recommendations is likely multifactorial and may be driven in part by publication timing, differences in evidence review, and regional variation in resources and treatment strategies.

3. Guidelines Review Summary

ASH Guidelines: The ASH 2020 guidelines for the management of VTE provide a structured, evidence-based framework for the diagnosis and treatment of DVT and PE using the GRADE methodology [3] Diagnostic recommendations are guided by pretest probability (PTP). In patients with low or intermediate PTP, the guidelines recommend highly sensitive D-dimer testing as the initial diagnostic step to reduce unnecessary imaging. However, a positive D-dimer result is insufficient for confirmation and should be followed by objective imaging, including ultrasonography for suspected DVT or computed tomography pulmonary angiography for PE. Patients with high PTP should proceed directly to imaging, with repeat ultrasonography recommended when the initial proximal lower-extremity ultrasound is negative despite persistent clinical suspicion.

For treatment, the ASH guidelines support outpatient management for clinically stable, low-risk patients with DVT or PE. Direct oral anticoagulants (DOACs), particularly apixaban and rivaroxaban, are preferred over vitamin K antagonists (VKAs) because of improved safety, ease of administration, and reduced need for bridging anticoagulation. A treatment duration of 3 to 6 months is generally recommended for primary therapy in both provoked and unprovoked VTE.

ASH discourages the routine use of thrombolysis and inferior vena cava (IVC) filters, reserving invasive interventions for hemodynamically unstable patients or those at imminent risk of limb loss. For secondary prevention, indefinite anticoagulation is recommended for patients with recurrent VTE or persistent chronic risk factors, with anticoagulation favored over aspirin. The guidelines also discourage routine use of compression stockings and prognostic testing to determine treatment duration, emphasizing individualized risk assessment and long-term management strategies [3].

CHEST Guidelines: The 2021 CHEST guideline update recommends assessment of Wells score for pretest probability combined with D-dimer testing and compression ultrasonography (CUS) for diagnosis [4]. For patients with a low probability score, a negative D-dimer rules out DVT. In patients with a high probability of DVT, imaging with proximal CUS or whole-leg ultrasound is recommended as the first test. DOACs are recommended as first-line therapy for most patients with acute DVT because of their favorable efficacy-safety profile compared with vitamin K antagonists.

For isolated distal DVT, CHEST adopts a more conservative approach than some other organizations. Patients without severe symptoms or risk factors for extension may undergo serial ultrasonographic surveillance rather than immediate anticoagulation. When anticoagulation is selected, a minimum treatment duration of three months is recommended.

CHEST discourages routine placement of IVC filters in addition to anticoagulation. Similarly, thrombolytic therapy is reserved for highly selected patients with extensive iliofemoral thrombosis, severe symptoms, low bleeding risk, and good functional status [4].

For extended secondary prevention, CHEST supports reduced-dose apixaban or rivaroxaban following completion of primary treatment in appropriately selected patients at continued risk for recurrence. For special patient populations, DOACs are preferred over low-molecular-weight heparin (LMWH) in patients with cancer, and extended anticoagulation beyond three months is generally recommended for those with active cancer. In contrast, patients with antiphospholipid syndrome should receive adjusted-dose VKA therapy, targeting an INR of 2.5, rather than DOACs.

These recommendations reflect an emphasis on balancing recurrent thrombosis risk against bleeding complications while minimizing treatment burden [4].

ESVS Guidelines: The 2021 ESVS Clinical Practice Guidelines recommend a structured diagnostic and therapeutic approach [5]. Initial evaluation should incorporate a validated pre-test probability model, such as the Wells score, combined with D-dimer testing. Patients with low clinical probability and a negative D-dimer can safely avoid imaging, whereas those with a positive D-dimer or high clinical probability require compression ultrasonography as the first-line diagnostic modality. Computed tomography venography is reserved for selected cases involving suspected iliocaval thrombosis or inconclusive ultrasound findings. Routine thrombophilia testing is discouraged and should be limited to carefully selected patients with unprovoked venous thromboembolism and a strong family history.

DOACs are recommended as first-line therapy for most patients, with outpatient management preferred when clinically appropriate. LMWH remains the treatment of choice in pregnancy and cancer-associated thrombosis. For distal DVT, anticoagulation decisions should be individualized according to symptom burden, risk of thrombus extension, and bleeding risk, with three months of therapy generally recommended. Early thrombus-removal strategies may be considered in selected patients with acute symptomatic iliofemoral DVT at high risk for post-thrombotic syndrome but are not recommended for femoropopliteal or calf-vein thrombosis.

Treatment duration is determined by provoking factors and recurrence risk. Three months of anticoagulation is recommended for most provoked events, whereas extended or indefinite therapy is advised for unprovoked or recurrent DVT in patients with acceptable bleeding risk. Inferior vena cava filters should be reserved for patients with proximal DVT and contraindications to anticoagulation. Aspirin is not recommended for secondary prevention when extended anticoagulation is indicated. Special populations, including patients with antiphospholipid syndrome, cancer, pregnancy, obesity, and severe renal impairment, require tailored management strategies [5].

NICE Guidelines: The NICE guideline on venous thromboembolic disease provides an evidence-based framework for the diagnosis and management of proximal DVT [6] Diagnostic evaluation is based on the two-level Wells score, which stratifies patients into likely and unlikely probability categories [6]. Patients classified as likely should undergo proximal leg vein ultrasonography within 4 hours, whereas those classified as unlikely should first undergo D-dimer testing, with imaging reserved for those with positive results. Age-adjusted D-dimer thresholds are recommended for patients older than 50 years. The guideline specifically addresses proximal DVT and does not cover isolated distal DVT [6].

For anticoagulation, apixaban and rivaroxaban are recommended as first-line therapies. Alternative regimens include LMWH followed by dabigatran or edoxaban, or LMWH overlapped with VKA until a therapeutic INR is achieved. Catheter-directed thrombolysis is reserved for selected patients with symptomatic iliofemoral DVT, symptom duration of less than 14 days, low bleeding risk, and favorable functional status. Inferior vena cava filters are not routinely recommended and are generally limited to patients with contraindications to anticoagulation or recurrent VTE despite treatment.

A minimum anticoagulation duration of 3 months is recommended for all cases of proximal DVT. Extended therapy should be individualized according to provoking factors, recurrence risk, and bleeding risk. Secondary prevention may involve continued direct oral anticoagulant therapy or aspirin in patients who decline anticoagulation. The guideline also outlines management considerations for special populations, including patients with antiphospholipid syndrome, active cancer, and renal impairment, emphasizing individualized therapeutic selection [6].

JCS/JPCPHS Guidelines: For diagnosis, the guideline recommends assessment of clinical probability, including the use of pre-test probability scores, combined with D-dimer testing for exclusion of VTE in low-risk patients [8]. Compression ultrasonography remains the first-line imaging modality for suspected DVT, whereas computed tomography is emphasized for pulmonary embolism diagnosis. Protein C, S, and antithrombin deficiencies should be considered for thrombophilia screening. Factor V Leiden and prothrombin G20210A mutations are rare in Asia. The guideline places greater emphasis than previous versions on evaluating disease severity, provoking factors, and risk stratification at presentation [8].

For treatment, anticoagulation remains the cornerstone of therapy. DOACs are now the preferred anticoagulants for most patients with acute DVT, largely replacing warfarin because of favorable efficacy and safety data generated in Japanese and international studies. Treatment duration should be individualized according to thrombotic and bleeding risk, with extended anticoagulation considered for patients with unprovoked DVT, recurrent events, active cancer, or persistent risk factors.

The guideline adopts a more selective approach to isolated distal (calf) DVT. Patients at low risk of thrombus extension may undergo serial ultrasound surveillance rather than routine anticoagulation, whereas anticoagulation is recommended for symptomatic patients or those with high-risk features. Catheter-directed thrombolysis and mechanical interventions are reserved for selected patients with extensive iliofemoral DVT, severe symptoms, or threatened limb viability. Compression therapy and early ambulation are encouraged to improve symptoms and reduce venous stasis [8].

ISTH Guidance Documents: Unlike ASH, CHEST, or NICE, the ISTH does not publish a single comprehensive guideline dedicated to adult acute DVT. Instead, recommendations are disseminated through Scientific and Standardization Committee (SSC) guidance documents addressing specific clinical scenarios and special populations [12,13,14,15].

Several SSC documents focus on cancer-associated thrombosis, upper-extremity DVT, antiphospholipid syndrome, obesity, and other complex thrombotic conditions. For catheter-associated upper-extremity DVT in cancer patients, ultrasonography is recommended as the preferred diagnostic modality, whereas D-dimer testing is not routinely recommended because of limited diagnostic utility in this setting [13].

Historically, LMWH represented the standard treatment for cancer-associated thrombosis. However, contemporary ISTH guidance recognizes that selected DOACs may be appropriate alternatives in carefully selected patients with acceptable bleeding risk [12].

In patients with thrombotic antiphospholipid syndrome, VKA remain the preferred anticoagulant, particularly in those with triple-positive antibody profiles, for whom DOACs are discouraged [14]. Similarly, ISTH guidance supports the use of standard-dose direct oral anticoagulants in most patients with obesity up to a body weight of 120 kg or body mass index of 40 kg/m² [15].

Because these recommendations focus on specific clinical circumstances rather than the entire spectrum of DVT diagnosis and treatment, ISTH guidance should be viewed as complementary to broader society guidelines rather than as a direct alternative to comprehensive DVT practice guidelines as below. Provoked DVT: discontinue anticoagulation. Unprovoked DVT: consider reduced-dose DOACs if bleeding risk is low. Recurrence episode: continue full-dose anticoagulation.

Catheter-directed thrombolysis and mechanical interventions are reserved for selected patients with extensive iliofemoral DVT, severe symptoms, or limb-threatening venous obstruction. IVC filters are reserved only if anticoagulation is contraindicated. Compression therapy and early ambulation are encouraged to improve symptoms and reduce venous stasis.

As secondary prevention in unprovoked events or persistent risk, indefinite anticoagulation may be warranted and aspirin can be considered [8].

Pediatrics: Of special interest, was the coverage of pediatric population on the clinical guidelines evaluated. The incidence of pediatric venous thromboembolism has increased substantially during the past two decades, largely because of increased survival among children with complex chronic illnesses, greater utilization of central venous catheters, and improved recognition of thrombotic disease [17,18].

The diagnosis of DVT in children differs considerably from adult practice. Clinical prediction rules such as the Wells score and D-dimer based diagnostic algorithms have not been adequately validated in pediatric populations and therefore cannot be routinely recommended [16]. Doppler ultrasonography remains the preferred first-line imaging modality, whereas computed tomography and magnetic resonance venography are reserved for selected situations requiring additional anatomical assessment [16].

Current pediatric management generally favors anticoagulation alone for most DVT events. LMWH has traditionally served as the cornerstone of therapy because of predictable pharmacokinetics and extensive pediatric experience, although direct oral anticoagulants are increasingly being incorporated into contemporary pediatric practice [16]. Thrombolysis and thrombectomy are reserved for highly selected patients with extensive thrombosis, threatened limb viability, or severe hemodynamic compromise.

4. Guidelines Comparison

A Despite broad agreement regarding the fundamental principles of acute DVT management, important differences remain among contemporary international guidelines.

Areas of agreement, disagreement, and evidence uncertainty were identified through comparative analysis and summarized in Table 3, and guidelines grading and strength of recommendations in Table 4.

5. Conclusions

Contemporary international guidelines for acute DVT management demonstrate broad consensus on key principles, including the use of structured diagnostic pathways combining clinical probability assessment, D-dimer testing, and compression ultrasonography, as well as the preferential use of direct oral anticoagulants as first-line therapy. However, important differences remain regarding anticoagulation duration, management of isolated distal DVT, indications for endovascular intervention, and the role of compression therapy. These variations reflect differing interpretations of limited evidence, regional healthcare resources, and population-specific thrombotic and bleeding risks. Future harmonization will require high-quality randomized trials in underrepresented populations, greater international collaboration, and the integration of emerging technologies such as Factor XIa inhibitors and artificial intelligence to advance precision-based, equitable DVT care worldwide.